The Federal Trade Commission has been operating at half-strength for more than a year and it’s unclear whether the Trump administration will bring the FTC back to full strength.
At full strength, the FTC has five presidentially appointed and Senate-confirmed commissioners.
Right now, it has only two sitting members, acting Chairman Maureen Ohlhausen (R) and Democratic Commissioner Terrell McSweeny. The administration has only nominated four new FTC commissioners and both Ohlhausen and McSweeny are expected to leave when the nominees are confirmed by the full Senate.
Ohlhausen has been nominated to serve as a judge on the U.S. Court of Claims.
The current slate of nominees is made up of Joseph Simons (R), who’s tapped for the chairmanship, Rohit Chopra (D), Noah Phillips (R), and Christine Wilson (R). The nominees indicated they would continue an active enforcement policy in the health-care arena.
For the pharmaceutical industry, this means reviewing mergers for anticompetitive effect. The new commissioners, once confirmed, aren’t likely to change that direction.
The FTC is also likely to continue aggressively policing other anticompetitive schemes in the pharmaceutical industry, such as patent litigation settlements that delay the entry of cheaper, generic drugs to the market.
If the nominees are confirmed without adding a fifth, the FTC would have a 3-1 Republican-Democrat ratio. This would be unusual because traditionally administrations present a full slate of nominees. Senate Democrats are pressing Trump for a fifth, Democratic nominee to round out the group.
Read my full story on the FTC nominees and the likely direction of the new commission here.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)